{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:57:51Z","timestamp":1792684671323,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004721","name":"The University of Tokyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study evaluated the efficacy and safety of initially implanted PreserFlo MicroShunt (PMS) in Japanese patients with exfoliation glaucoma (XFG). Using propensity score matching, intraocular pressure (IOP) control rates were compared between patients with XFG and primary open-angle glaucoma (POAG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study design<\/jats:title>\n                    <jats:p>Retrospective observational study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study reviewed 31 eyes of 31 patients with XFG who underwent initial PMS implantation with mitomycin C. IOP, medication scores, and corneal endothelial cell density (CECD) were assessed preoperatively and at up to 6 months postoperatively. Kaplan\u2013Meier analysis was used to estimate the 6-month survival rate, defined as an IOP reduction of &gt; 20% from baseline and an IOP &lt;\u00a015 mmHg. The incidences of needling, reoperation, and complications were also assessed. IOP control was compared between XFG and propensity-score-matched POAG patients using the log-rank test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At 6 months, the mean IOP had decreased significantly, from 22.3\u202f\u00b1\u202f6.6 to 14.7 \u00b1\u202f6.6\u202fmmHg, and the medication score had declined from 4.5 to 1.4. CECD decreased from 2127 to 1902 cells\/mm\n                      <jats:sup>2<\/jats:sup>\n                      , although this was not statistically significant. The complete success rate (without any glaucoma medications or intervention) was 48%. Postoperative complications included anterior chamber hemorrhage and choroidal detachment. Needling was performed in nine eyes (29.0%), and additional surgery was performed in five eyes (16.1%). Compared to POAG patients (11.9 mmHg), XFG patients had higher postoperative IOP (14.8 mmHg) and higher medication scores (0.5 vs 1.4,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.04) and a lower success rate (62.2% vs 41.7%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PMS in Japanese patients with XFG resulted in a significant IOP reduction over 6 months, with a relatively favorable safety profile. However, its efficacy was slightly inferior to that in POAG, implying potential differences in PMS responsiveness between glaucoma subtypes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10384-025-01265-5","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T04:59:32Z","timestamp":1756184372000},"page":"210-220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Short-term outcomes of the PreserFlo MicroShunt in Japanese patients with exfoliation glaucoma: a comparison with primary open-angle glaucoma using propensity score matching"],"prefix":"10.1007","volume":"70","author":[{"given":"Teruki","family":"Yamae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1411-1476","authenticated-orcid":false,"given":"Rei","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruyuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurika","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hotaka","family":"Nemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Honjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiroaki","family":"Shirato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Aihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"1265_CR1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10384-022-00970-9","volume":"67","author":"Y. Kiuchi","year":"2023","unstructured":"Kiuchi Y, Inoue T, Shoji N, Nakamura M, Tanito M. The Japan Glaucoma Society guidelines for glaucoma 5th edition. Jpn J Ophthalmol. 2023; 67:189\u2013254.","journal-title":"Jpn J Ophthalmol"},{"issue":"Suppl 1","key":"1265_CR2","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1097\/IJG.0000000000000906","volume":"27","author":"M Ozaki","year":"2018","unstructured":"Ozaki M. Mechanisms of glaucoma in exfoliation syndrome. J Glaucoma. 2018;27(Suppl 1):S83\u20136.","journal-title":"J Glaucoma"},{"key":"1265_CR3","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/j.ophtha.2009.06.042","volume":"116","author":"A Heijl","year":"2009","unstructured":"Heijl A, Bengtsson B, Hyman L, Leske MC. Natural history of open-angle glaucoma. Ophthalmology. 2009;116:2271\u20136.","journal-title":"Ophthalmology"},{"key":"1265_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/archopht.1997.01100150184006","volume":"115","author":"AG Konstas","year":"1997","unstructured":"Konstas AG, Mantziris DA, Stewart WC. Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma. Arch Ophthalmol. 1997;115:182\u20135.","journal-title":"Arch Ophthalmol"},{"issue":"Suppl 1","key":"1265_CR5","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1097\/IJG.0000000000000947","volume":"27","author":"TT Kivel\u00e4","year":"2018","unstructured":"Kivel\u00e4 TT. Histopathology of exfoliation syndrome. J Glaucoma. 2018;27(Suppl 1):S38-43.","journal-title":"J Glaucoma"},{"key":"1265_CR6","doi-asserted-by":"publisher","first-page":"814","DOI":"10.3390\/jcm10040814","volume":"10","author":"M Tanito","year":"2021","unstructured":"Tanito M, Sugihara K, Tsutsui A, Hara K, Manabe K, Matsuoka Y. Midterm results of microhook ab interno trabeculotomy in initial 560 eyes with glaucoma. J Clin Med. 2021;10:814.","journal-title":"J Clin Med"},{"key":"1265_CR7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.4103\/ijo.IJO_1130_17","volume":"66","author":"R Sihota","year":"2018","unstructured":"Sihota R, Angmo D, Ramaswamy D, Dada T. Simplifying, \u201ctarget\u201d intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma. Indian J Ophthalmol. 2018;66:495\u2013505.","journal-title":"Indian J Ophthalmol"},{"key":"1265_CR8","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1097\/IJG.0000000000001818","volume":"30","author":"M Ayala","year":"2021","unstructured":"Ayala M. Lower success in trabeculectomies in exfoliation compared with primary open-angle glaucoma patients in Sweden. J Glaucoma. 2021;30:e237\u201345.","journal-title":"J Glaucoma"},{"key":"1265_CR9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/IJG.0000000000000365","volume":"26","author":"SH Lim","year":"2017","unstructured":"Lim SH, Cha SC. Long-term outcomes of mitomycin-C trabeculectomy in exfoliative glaucoma versus primary open-angle glaucoma. J Glaucoma. 2017;26:303\u201310.","journal-title":"J Glaucoma"},{"key":"1265_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/00061198-199902000-00006","volume":"8","author":"NX Nguyen","year":"1999","unstructured":"Nguyen NX, K\u00fcchle M, Martus P, Naumann GO. Quantification of blood\u2013aqueous barrier breakdown after trabeculectomy: pseudoexfoliation versus primary open-angle glaucoma. J Glaucoma. 1999;8:18\u201323.","journal-title":"J Glaucoma"},{"issue":"Suppl 1","key":"1265_CR11","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1159\/000267859","volume":"27","author":"M K\u00fcchle","year":"1995","unstructured":"K\u00fcchle M, Nguyen NX, Hannappel E, Naumann GO. The blood-aqueous barrier in eyes with pseudoexfoliation syndrome. Ophthalmic Res. 1995;27(Suppl 1):136\u201342.","journal-title":"Ophthalmic Res"},{"key":"1265_CR12","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.ophtha.2021.05.023","volume":"128","author":"ND Baker","year":"2021","unstructured":"Baker ND, Barnebey HS, Moster MR, Stiles MC, Vold SD, Khatana AK, et al. Ab-externo MicroShunt versus trabeculectomy in primary open-angle glaucoma: one-year results from a 2-year randomized, multicenter study. Ophthalmology. 2021;128:1710\u201321.","journal-title":"Ophthalmology"},{"key":"1265_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ogla.2021.07.008","volume":"5","author":"HJM Beckers","year":"2022","unstructured":"Beckers HJM, Aptel F, Webers CAB, Bluwol E, Mart\u00ednez-de-la-Casa JM, Garc\u00eda-Feijo\u00f3 J, et al. Safety and effectiveness of the PRESERFLO\u00ae MicroShunt in primary open-angle glaucoma: results from a 2-year multicenter study. Ophthalmol Glaucoma. 2022;5:195\u2013209.","journal-title":"Ophthalmol Glaucoma."},{"key":"1265_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ajo.2020.02.020","volume":"215","author":"MB Schlenker","year":"2020","unstructured":"Schlenker MB, Durr GM, Michaelov E, Ahmed IIK. Intermediate outcomes of a novel standalone Ab externo SIBS Microshunt with mitomycin C. Am J Ophthalmol. 2020;215:141\u201353.","journal-title":"Am J Ophthalmol"},{"key":"1265_CR15","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ogla.2023.04.002","volume":"6","author":"JJ Armstrong","year":"2023","unstructured":"Armstrong JJ, De Francesco T, Ma J, Schlenker MB, Ahmed IIK. Ab externo SIBS Microshunt with mitomycin C for open-angle glaucoma: three-year results as a primary surgical intervention. Ophthalmol Glaucoma. 2023;6:480\u201392.","journal-title":"Ophthalmol Glaucoma."},{"key":"1265_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bjophthalmol-2020-317299","volume":"106","author":"GM Durr","year":"2022","unstructured":"Durr GM, Schlenker MB, Samet S, Ahmed IIK. One-year outcomes of stand-alone ab externo SIBS microshunt implantation in refractory glaucoma. Br J Ophthalmol. 2022;106:71\u20139.","journal-title":"Br J Ophthalmol"},{"key":"1265_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ogla.2021.08.005","volume":"5","author":"AM Fea","year":"2022","unstructured":"Fea AM, Laffi GL, Martini E, Economou MA, Caselgrandi P, Sacchi M, et al. Effectiveness of MicroShunt in patients with primary open-angle and pseudoexfoliative glaucoma: a retrospective European multicenter study. Ophthalmol Glaucoma. 2022;5:210\u20138.","journal-title":"Ophthalmol Glaucoma."},{"key":"1265_CR18","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1111\/aos.14602","volume":"99","author":"LMJ Scheres","year":"2021","unstructured":"Scheres LMJ, Kujovic-Aleksov S, Ramdas WD, de Crom R, Roelofs LCG, Berendschot T, et al. XEN(\u00ae) Gel Stent compared to PRESERFLO\u2122 MicroShunt implantation for primary open-angle glaucoma: two-year results. Acta Ophthalmol. 2021;99:e433\u201340.","journal-title":"Acta Ophthalmol"},{"key":"1265_CR19","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1007\/s00417-023-06075-4","volume":"261","author":"M Jamke","year":"2023","unstructured":"Jamke M, Herber R, Haase MA, Jasper CS, Pillunat LE, Pillunat KR. Preserflo\u2122 microshunt versus trabeculectomy: 1-year results on efficacy and safety. Graefes Arch Clin Exp Ophthalmol. 2023;261:2901\u201315.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1265_CR20","volume":"14","author":"S Fili","year":"2022","unstructured":"Fili S, Kontopoulou K, Vastardis I, Perdikakis G, Kohlhaas M. PreserFlo\u2122 MicroShunt versus trabeculectomy in patients with moderate to advanced open-angle glaucoma: 12-month follow-up of a single-center prospective study. Cureus. 2022;14: e28288.","journal-title":"Cureus."},{"key":"1265_CR21","doi-asserted-by":"publisher","first-page":"180","DOI":"10.4103\/joco.joco_298_21","volume":"34","author":"S Fili","year":"2022","unstructured":"Fili S, Kontopoulou K, Vastardis I, Perdikakis G, Bechrakis N, Kohlhaas M. Preserflo\u2122 microshunt combined with phacoemulsification versus Preserflo\u2122 microshunt as a standalone procedure in patients with medically resistant open-angle glaucoma. J Curr Ophthalmol. 2022;34:180\u20136.","journal-title":"J Curr Ophthalmol"},{"key":"1265_CR22","volume":"15","author":"KJ Habbe","year":"2023","unstructured":"Habbe KJ, Kohlhaas M, Fili S. PreserFlo\u2122 MicroShunt versus Ab Externo canaloplasty in patients with moderate to advanced open-angle glaucoma: 12-month follow-up of a single-center retrospective study. Cureus. 2023;15: e35185.","journal-title":"Cureus."},{"key":"1265_CR23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/aos.15727","volume":"102","author":"AD B\u00f8hler","year":"2024","unstructured":"B\u00f8hler AD, Traustad\u00f3ttir VD, Hagem AM, T\u00f8nset TS, Drolsum L, Kristianslund O. Hypotony in the early postoperative period after MicroShunt implantation versus trabeculectomy: a registry study. Acta Ophthalmol. 2024;102:186\u201391.","journal-title":"Acta Ophthalmol"},{"key":"1265_CR24","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1038\/s41433-022-02368-w","volume":"37","author":"G Triolo","year":"2023","unstructured":"Triolo G, Wang J, Aguilar-Munoa S, Jayaram H, Barton K. Preserflo microshunt implant for the treatment of refractory uveitic glaucoma: 36-month outcomes. Eye (Lond). 2023;37:2535\u201341.","journal-title":"Eye (Lond)"},{"key":"1265_CR25","doi-asserted-by":"publisher","first-page":"4474","DOI":"10.3390\/jcm12134474","volume":"12","author":"JJ Storp","year":"2023","unstructured":"Storp JJ, Vietmeier FE, Mert\u00e9 RL, Koch R, Zimmermann JA, Eter N, et al. Long-term outcomes of the PRESERFLO MicroShunt implant in a heterogeneous glaucoma cohort. J Clin Med. 2023;12:4474.","journal-title":"J Clin Med"},{"key":"1265_CR26","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10384-024-01159-y","volume":"69","author":"H Suzuki","year":"2025","unstructured":"Suzuki H, Sakata R, Yamae T, Ishiyama Y, Sugimoto K, Saito H, et al. Short-term efficacy and safety of Preserflo Microshunt in Japanese patients with medically treated primary open-angle glaucoma. Jpn J Ophthalmol. 2025;69:287\u201395.","journal-title":"Jpn J Ophthalmol"},{"key":"1265_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ajo.2023.06.009","volume":"255","author":"MB Schlenker","year":"2023","unstructured":"Schlenker MB, Armstrong JJ, De Francesco T, Ahmed IIK. All consecutive ab externo SIBS microshunt implantations with mitomycin C: one-year outcomes and risk factors for failure. Am J Ophthalmol. 2023;255:125\u201340.","journal-title":"Am J Ophthalmol"},{"key":"1265_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0256670","volume":"16","author":"M Nobl","year":"2021","unstructured":"Nobl M, Freissinger S, Kassumeh S, Priglinger S, Mackert MJ. One-year outcomes of microshunt implantation in pseudoexfoliation glaucoma. PLoS One. 2021;16: e0256670.","journal-title":"PLoS One"},{"key":"1265_CR29","doi-asserted-by":"publisher","first-page":"6132","DOI":"10.3390\/jcm13206132","volume":"13","author":"H Wakuda","year":"2024","unstructured":"Wakuda H, Aoki R, Nakakura S. Postoperative outcomes of PreserFlo MicroShunt in patients with exfoliation glaucoma. J Clin Med. 2024;13:6132.","journal-title":"J Clin Med"},{"key":"1265_CR30","doi-asserted-by":"publisher","first-page":"28457","DOI":"10.1038\/s41598-024-80093-y","volume":"14","author":"R Sakata","year":"2024","unstructured":"Sakata R, Aihara M, Shirato S. Transient hyphema associated with PRESERFLO(\u00ae) microshunt surgery using a double-step knife in patients with glaucoma. Sci Rep. 2024;14:28457.","journal-title":"Sci Rep"},{"key":"1265_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/BSD.0000000000000932","volume":"33","author":"LT Kane","year":"2020","unstructured":"Kane LT, Fang T, Galetta MS, Goyal DKC, Nicholson KJ, Kepler CK, et al. Propensity score matching: a statistical method. Clin Spine Surg. 2020;33:120\u20132.","journal-title":"Clin Spine Surg."},{"key":"1265_CR32","unstructured":"Anderson D, Patella V. Automated static perimetry 2nd edition. Mosby; 1999."},{"key":"1265_CR33","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ophtha.2023.09.023","volume":"131","author":"JF Panarelli","year":"2024","unstructured":"Panarelli JF, Moster MR, Garcia-Feijoo J, Flowers BE, Baker ND, Barnebey HS, et al. Ab-externo microshunt versus trabeculectomy in primary open-angle glaucoma: two-year results from a randomized, multicenter study. Ophthalmology. 2024;131:266\u201376.","journal-title":"Ophthalmology"},{"key":"1265_CR34","doi-asserted-by":"crossref","unstructured":"Bhayani R, Mart\u00ednez de la Casa JM, Figus M, Klabe K, Rabiolo A, Mercieca K. Short-term safety and efficacy of Preserflo\u2122 Microshunt in glaucoma patients: a multicentre retrospective cohort study. Eye (Lond). 2023; 37:644-9.","DOI":"10.1038\/s41433-022-01995-7"},{"key":"1265_CR35","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1007\/s00417-020-04962-8","volume":"259","author":"M Tanito","year":"2021","unstructured":"Tanito M, Hara K, Takai Y. Anterior chamber flare in primary open-angle glaucoma and exfoliation glaucoma after trabeculotomy. Graefes Arch Clin Exp Ophthalmol. 2021;259:1665\u20137.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1265_CR36","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.11.2.32","volume":"11","author":"I Sugimoto","year":"2022","unstructured":"Sugimoto I, Usui S, Okazaki T, Kawashima R, Miki A, Kawasaki R, et al. Early three-dimensional intrableb structural changes in primary open-angle glaucoma and exfoliation glaucoma after Ex-PRESS surgery. Transl Vis Sci Technol. 2022;11: 32.","journal-title":"Transl Vis Sci Technol"},{"key":"1265_CR37","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.ophtha.2018.12.029","volume":"126","author":"R Sakata","year":"2019","unstructured":"Sakata R, Yoshitomi T, Iwase A, Matsumoto C, Higashide T, Shirakashi M, et al. Factors associated with progression of Japanese open-angle glaucoma with lower normal intraocular pressure. Ophthalmology. 2019;126:1107\u201316.","journal-title":"Ophthalmology"},{"key":"1265_CR38","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/bjophthalmol-2018-313375","volume":"104","author":"SU Baek","year":"2020","unstructured":"Baek SU, Ha A, Kim DW, Jeoung JW, Park KH, Kim YK. Risk factors for disease progression in low-teens normal-tension glaucoma. Br J Ophthalmol. 2020;104:81\u20136.","journal-title":"Br J Ophthalmol"},{"key":"1265_CR39","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.ophtha.2007.10.031","volume":"115","author":"J Caprioli","year":"2008","unstructured":"Caprioli J, Coleman AL. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology. 2008;115:1123-9.e3.","journal-title":"Ophthalmology"},{"key":"1265_CR40","first-page":"251584142211499","volume":"15","author":"CJ Gassel","year":"2023","unstructured":"Gassel CJ, Dzhelebov DN, Voykov B. Detailed intraocular pressure curve by telemetric tonometry with an implanted pressure sensor before and after PreserFlo(\u00ae) MicroShunt implantation: a case report. Ther Adv Ophthalmol. 2023;15:25158414221149930.","journal-title":"Ther Adv Ophthalmol."},{"key":"1265_CR41","doi-asserted-by":"crossref","unstructured":"Ibarz-Barber\u00e1 M, Morales-Fern\u00e1ndez L, Corroto-Cuadrado A, Martinez-Gald\u00f3n F, Ta\u00f1\u00e1-Rivero P, G\u00f3mez de Lia\u00f1o R, et al. Corneal endothelial cell loss after PRESERFLO\u2122 MicroShunt implantation in the anterior chamber: anterior segment OCT tube location as a risk factor. Ophthalmol Ther. 2022;11:293\u2013310.","DOI":"10.1007\/s40123-021-00428-0"},{"key":"1265_CR42","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/IJG.0000000000000219","volume":"24","author":"Y Aoyama","year":"2015","unstructured":"Aoyama Y, Murata H, Aihara M. Targeting a low-teen intraocular pressure by trabeculectomy with a fornix-based conjunctival flap: continuous Japanese case series by a single surgeon. J Glaucoma. 2015;24:225\u201332.","journal-title":"J Glaucoma"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01265-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-025-01265-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01265-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:36:14Z","timestamp":1772166974000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-025-01265-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1265"],"URL":"https:\/\/doi.org\/10.1007\/s10384-025-01265-5","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T. Yamae, None; R. Sakata, Royalties or licenses (Santen), Consulting fees (Santen), Payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events (Santen, Senju, Otsuka, Kowa), Participation on a Data Safety Monitoring Board or Advisory Board (Santen), Receipt of equipment, materials, drugs, medical writing, gifts or other services (Santen, Kowa); H. Suzuki, None; Y. Aoyama, None; H. Nemoto, Grant (Novartis Pharma Grants for Basic Research 2022), Payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events (Santen, Kowa, TOPCON); H. Saito, Payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events (Santen, Senju, Otsuka, Kowa, ZEISS, TOPCON, AbbVie, Novartis, Viatris, Rhoto, Sandoz); M. Honjo, Grants or contracts from any entity (Santen, Alcon), Consulting fees (Santen), Payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events (Santen, Otsuka, Kowa, Novartis, Senju), Participation on a Data Safety Monitoring Board or Advisory Board (Santen), Receipt of equipment, materials, drugs, medical writing, gifts or other services (Santen, Kowa); S. Shirato, Consulting fees (Santen, Otsuka, Senju, Kowa); M. Aihara, Grants or contracts from any entity (Santen, Alcon, Pfizer, Otsuka, Johnson & Johnson, TOMEY, CREWT Medical Systems, Senju, Novartis, Kowa, Wakamoto, Glaukos, Ono, Sato), Consulting fees (Santen, Alcon, Kowa, Wakamoto, Glaukos, Astellas, Senju, Pfizer, Otsuka, HOYA, IRIDEX Medical Systems), Payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events (Santen, Senju, Alcon, Novartis, Pfizer, Kowa, Otsuka, Johnson & Johnson, HOYA, Glaukos, TOMEY, IRIDEX, CREWT Medical Systems, CANON, ZEISS, Sato, Wakamoto, Astellas), Participation on a Data Safety Monitoring Board or Advisory Board (Santen, Senju, HOYA, Kowa), Receipt of equipment, materials, drugs, medical writing, gifts or other services (Kowa, Santen).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}